Advances in the macrolides and quinolones

Infectious Disease Clinics of North America

Volumn 12, Issue 3, 1998, Pages 647-670

  Boswell, F J ^a   Wise, R ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; DIRITHROMYCIN; ERYTHROMYCIN; JOSAMYCIN; LEVOFLOXACIN; MACROLIDE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CHEMICAL STRUCTURE; DRUG ACTIVITY; HAEMOPHILUS INFLUENZAE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MORAXELLA CATARRHALIS; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STRUCTURE ACTIVITY RELATION;

EID: 0031685173     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70203-8     Document Type: Article

References (117)

1. Agouridas C, Benedetti Y, Denis A, et al: Ketolides, a new distinct semi-synthetic class of macrolides [abstract F164]. In Abstracts of the 34th Interscience Conference of Antimicrobial Agents and Chemotherapy, Orlando, October 4–7, 1994, p 227
2. Agouridas C, Bonnefoy A, Chantot JF: In vitro antibacterial activity of HMR 3647, a novel ketolide highly active against respiratory pathogens [abstract F112]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 165
3. Agouridas C, Bonnefoy A, Chantot JF: Susceptibility testing conditions used and the antibacterial activity of RU 004 [abstract F169]. In Abstracts of the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, September 15–18, 1995, p 142
4. Amano H, Hayashi N, Ohshita Y, et al: WQ-2724 and WQ-2743, novel fluoroquinolones: In vitro and in vivo activities, pharmacokinetics and toxicity [abstract F163]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 173
5. Asaka T, Kashimura M, Tanikawa T, et al: New macrolide antibiotics, acylides (3- O -acyl-5- O -desosaminylerythronolides); synthesis and biological properties [abstract F262]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 190
6. F. Baquero R. Cantón In vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens J Antimicrob Chemother 37 Suppl A 1996 1 18
7. A.L. Barry P.C. Fuchs In vitro activities of a streptogramin (RP59500), three macrolides and an azalide against four respiratory tract pathogens Antimicrob Agents Chemother 39 1995 238 240
8. Barry AL, Brown SD, Fuchs PC: Antipneumococcal activity of a ketolide (HMR 3647) and seven related drugs in vitro [abstract F107]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 164
9. A.L. Barry P.C. Fuchs S.D. Brown Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from outpatients in the USA J Antimicrob Chemother 40 1997 139 140
10. M. Barza E. Eisenberg Clarithromycin and azithromycin Infect Dis Clin Pract 5 1996 291 302
11. C.M. Bébéar H. Renaudin M.D. Aydin In vitro activity of ketolides against mycoplasmas J Antimicrob Chemother 39 1997 669 670
12. Biedenbach DJ, Marshall SA, Marco F, et al: Antimicrobial activity of LB20304 against Legionella species and anaerobic bacteria using reference agar dilution methods [abstract F170]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 174
13. F.J. Boswell J.M. Andrews J.P. Ashby The in vitro activity of HMR 3647, a new ketolide antimicrobial agent J Antimicrob Chemother 41 1998 149 153
14. F.J. Boswell J.M. Andrews R. Wise Bactericidal activity of trovafloxacin under anaerobic and aerobic conditions Infect Dis Clin Pract 5 Suppl 3 1996 113 116
15. F.J. Boswell J.M. Andrews R. Wise Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect Antimicrob Agents Chemother 41 1997 1377 1379
16. F.J. Boswell J.M. Andrews R. Wise Pharmacodynamic properties of HMR 3004, a novel ketolide, demonstrated by studies of time-kill kinetics and postantibiotic effect Clin Microbiol Infect 4 1998 186 191
17. Boswell FJ, Andrews JM, Wise R: Pharmacodynamic properties of HMR 3647, a novel ketolide, demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother, in press
18. N.P. Brenwald M.J. Gill R. Wise The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin J Antimicrob Chemother 40 1997 458 460
19. G.M. Brighty A.A. Nagel J. Boroher Synthesis, in vitro and in vivo activity of novel 9-deoxo-9a-aza-homoerythromycin A derivatives, a new class of macrolide antibiotics, the azalides J Antibiot 41 1988 1029 1047
20. K.E. Brighty T.D. Gootz The chemistry and biological profile of trovafloxacin J Antimicrob Chemother 39 Suppl B 1997 1 14
21. A.B. Brueggemann K.C. Kugler G.V. Doern In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis Antimicrob Agents Chemother 41 1997 1594 1597
22. A. Bryskier Fluoroquinolones: Mechanisms of action and resistance Int J Antimicrob Agents 2 1993 151 184
23. A. Bryskier C. Agouridas J.C. Gasc Classification of macrolide antibiotics Bryskier A.J. Butzler J.P. Neu H.C. Macrolides 1993 Arnette Blackwell Paris 5 66
24. J. Child J. Andrews F. Boswell The in-vitro activity of CP 99, 219, a new naphthyridone antimicrobial agent: A comparison with fluoroquinolone agents J Antimicrob Chemother 35 1995 869 876
25. Chu DTW, Or YS: New agents to overcome macrolide resistance [abstract S85]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 394
26. J. Clancy J. Petitpas F. Dib-Hajj Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA , from Streptococcus pyogenes Mol Microbiol 22 1996 867 879
27. M.A. Cooper J.M. Andrews J.P. Ashby In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent J Antimicrob Chemother 26 1990 667 676
28. M.A. Cooper J.M. Andrews R. Wise Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions J Antimicrob Chemother 28 1991 399 405
29. W.A. Craig S. Gudmundsson Postantibiotic effect Lorian V. Antibiotics in Laboratory Medicine ed 4 1996 Williams & Wilkins Baltimore 296 329
30. Craig WA, Rikardsdottir S, Watanabe Y: In-vivo and in-vitro postantibiotic effects (PAEs) of azithromycin [abstract 45]. In Abstracts of the 32nd Interscience Conference of Antimicrobial Agents and Chemotherapy, Anaheim, October 11–14, 1992, p 118
31. R. Davis A. Markham J.A. Balfour Ciprofloxacin: An updated review of its pharmacology, therapeutic efficacy and tolerability Drugs 51 1996 1019 1074
32. E.A. Debbia G. Molinari P. Paglia Post-antibiotic effect of azithromycin on respiratory tract pathogens Drugs Exp Clin Res 16 1990 651 659
33. Diculencu D, Andrews JM, Boswell FJ, et al: The postantibiotic effect of azithromycin against respiratory pathogens [abstract F172]. In Abstracts of the 1st European Congress of Chemotherapy, Glasgow, May, 1996
34. J.M. Domagala Structure-activity and structure–side-effect relationships for the quinolone antibacterials J Antimicrob Chemother 33 1994 685 706
35. Donati M, Rumpianesi F, Marchetti F, et al: Comparative in vitro activity of levofloxacin (LVFX) against Chlamydia pneumoniae, Chlamydia trachomatis and Chlamydia psittaci [abstract E154]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 141
36. Dornbusch K, Olofsson C, Holm S: Post-antibiotic effect (PAE) of dirithromycin (DM) and erythromycin (EM) against respiratory tract pathogens [abstract 657]. In Abstracts of the 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy, New Orleans, October 17–20, 1993
37. K. Drlica X. Zhao DNA gyrase, topoisomerase IV, and the 4-quinolones Microbiol Mol Biol Rev 61 1997 377 392
38. C.J. Dunn L.B. Barradell Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections Drugs 51 1996 483 505
39. Ednie LM, Jacobs M, Appelbaum P: Anti-anaerobic activity of the ketolide RU 66647 compared to 12 other compounds [abstract F122]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 167
40. L.M. Ednie S.K. Spangler M.R. Jacobs Antianaerobic activity of the ketolide RU 64004 compared to activities of four macrolides, five β-lactams, clindamycin, and metronidazole Antimicrob Agents Chemother 41 1997 1037 1041
41. Elliott RL, Pireh D, Griesgraber G, et al: Synthesis and in vitro activity of novel 2, 3-anhydro-6- O -methyl-11, 12-carbamate erythromycin analogues [abstract F265]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 191
42. Entenza JM, Giddey M, Glauser MP, et al: Activity of the novel quinolone Y-688 in vitro and in the treatment (Rx) of experimental endocarditis (EE) due to ciprofloxacin resistant (CIP-R) Staphylococcus aureus [abstract F167]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 174
43. R.J. Fass In vitro activity of BAY 12-8039, a new 8-methoxyquinolone Antimicrob Agents Chemother 41 1997 1818 1824
44. D. Felmingham M.J. Robbins K. Ingley In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates J Antimicrob Chemother 39 Suppl B 1997 43 50
45. Felmingham D, Robbins MJ, Leakey A, et al: The comparative in vitro activity of HMR 3647: A ketolide antimicrobial against clinical bacterial isolates [abstract F116]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 166
46. Felmingham D, Robbins MJ, Mathia S, et al: Results of a European multicentre study of the comparative in vitro susceptibility of gram-negative bacteria to levofloxacin [abstract P1150]. In Abstracts of the 8th European Congress of Clinical Microbiology and Infectious Disease, Lausanne, May 25–28, 1997
47. P.B. Fernandes W.R. Baker L.A. Frieberg New macrolides active against Streptococcus pyogenes with inducible or constitutive type of macrolide lincosamide streptogramin B resistance Antimicrob Agents Chemother 33 1989 78 81
48. G. Foulds R.M. Sheperd R.B. Johnson The pharmacokinetics of azithromycin in human serum and tissues J Antibiot 25 Suppl A 1990 73 82
49. J.C. Fung-tomc E. Huczko T. Stickle Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides Antimicrob Agents Chemother 39 1995 533 538
50. J.C. Gasc A. Bryskier Structure activity relationships of macrolides Bryskier A.J. Butzler J.-P. Neu H.C. Macrolides 1993 Arnette Blackwell Paris 67 82
51. George JT, Morrissey I: Purification of topoisomerase IV from Streptococcus pneumoniae C3LN4 and inhibition by fluoroquinolones [abstract C90]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 61
52. K.L. Goa H.M. Bryson A. Markham Sparfloxacin: A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections Drugs 53 1997 700 725
53. T.D. Gootz K.E. Brighty Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects Med Res Rev 16 1996 433 486
54. Griesgraber G, Elliott RL, Kramer MJ, et al: Synthesis and in vitro activity of novel 2, 3-anhydro-11-hydrazo-6- O -methyl-11, 12-carbamate erythromycin derivatives [abstract F267]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 191
55. Gruneberg RN, Felmingham D, The Alexander Project Group: The Alexander Project 1995: International surveillance of antimicrobial resistance amongst community-acquired lower respiratory tract pathogens [abstract E101]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 131
56. D.J. Hardy D.M. Hensey J.M. Beyer Comparative in vitro activities of the new 14-, 15-, and 16-membered macrolides Antimicrob Agents Chemother 32 1988 1710 1719
57. D.J. Hardy R.N. Swanson R.A. Rode Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans Antimicrob Agents Chemother 34 1990 1407 1413
58. Hayashi K, Todo Y, Hamamoto S, et al: T-3811, a novel des-F(6)-quinolone: Synthesis and in vitro activity of 7-(isoindolin-5-yl) derivatives [abstract F158]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 173.
59. D.W. Hecht H.M. Wexler In vitro susceptibility of anaerobes to quinolones in the United States Clin Infect Dis 23 Suppl 1 1996 2 8
60. Hoban DJ, Karlowsky JA, Kabini AM, et al: The postantibiotic effect (PAE) of sparfloxacin against respiratory pathogens [abstract A93]. In Abstracts of the 36th Interscience Conference of Antimicrobial Agents and Chemotherapy, New Orleans, September 15–18, 1996, p 18
61. J.A.A. Hoogkamp-Korstanje In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, perfloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections J Antimicrob Chemother 40 1997 427 431
62. J.A.A. Hoogkamp-Korstanje S.I.S. Dirks-Go P. Kabel Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin J Antimicrob Chemother 39 1997 411 414
63. D.C. Hooper Quinolones Mandell G.L. Bennett J.E. Dolin R. Principles and Practice of Infectious Diseases ed 4 1995 Churchill-Livingstone New York 364 376
64. B.M.A. Howard R.J. Pinney J.T. Smith Contributions of post-antibiotic lag and repair and recovery to the post-antibiotic effects of ciprofloxacin on Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus pyogenes Chemotherapy 39 1993 22 31
65. Z. Itoh T. Suzuki M. Nakawa Structure activity relation among macrolide antibiotics in initiation of interdigestive migrating contractions in the canine gastrointestinal tract Am J Physiol 248 1985 6320 6325
66. C. Jamjian D.J. Biedenbach R.N. Jones In vitro evaluation of a novel ketolide antimicrobial agent, RU 64004 Antimicrob Agents Chemother 41 1997 454 459
67. G.E. Kenny F.D. Cartwright Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae , and Ureaplasma urealyticum to a new quinolone, OPC 17116 Antimicrob Agents Chemother 37 1993 1726 1727
68. J.H. Kim J.A. Kang Y.G. Kim In vitro and in vivo antibacterial efficacies of CFC 222, a new fluoroquinolone Antimicrob Agents Chemother 41 1997 2209 2213
69. H.A. Kirst G.D. Sides New directions for macrolide antibiotics: Structural modifications and in vitro activity Antimicrob Agents Chemother 33 1989 1413 1418
70. Kitzis MD, Goldstein FW, Bismuth R, et al: Comparative in vitro activity of HMR 3647, a new ketolide antibiotic against S. aureus (SA) and coagulase negative staphylococci (CNS) [abstract F111]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 165
71. Y. Kumagai J.I. Kato K. Hoshino Quinolone-resistant mutants of Escherichia coli DNA topoisomerase IV parC gene Antimicrob Agents Chemother 40 1996 710 714
72. C.J. Lai B. Weisblum Altered methylation of ribosomal RNA in an erythromycin resistant strain of Staphylococcus aureus Proc Natl Acad Sci USA 68 1971 856 860
73. Martin G, Waters C, Paparello S, et al: Postantibiotic effects of clarithromycin (C) and erythromycin (E) against M. catarrhalis [abstract 654]. In Abstracts of the 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy, New Orleans, September 28–October 1, 1993
74. H.D. Langtry R.N. Brogden Clarithromycin: A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients Drugs 53 1997 973 1004
75. R. Leclercq P. Courvalin Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification Antimicrob Agents Chemother 35 1991 1267 1272
76. R. Leclercq P. Courvalin Mechanisms of resistance to macrolides and functionally related antibiotics Bryskier A.J. Butzler J.P. Neu H.C. Macrolides 1993 Arnette Blackwell Paris 125 142
77. Marie-Bigot C, Decre D, Muller C, et al: In vitro activity of a novel ketolide antimicrobial agent HMR 3647 compared to erythromycin (ERY), roxithromycin (ROX), azithromycin (AZI) and clarithromycin (CLA) [abstract F117]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 166
78. Martin G, Waters C, Paparello S, et al: Postantibiotic effects of clarithromycin (C) and erythromycin (E) against M. catarrhalis [abstract 654]. In Abstracts of the 33rd Interscience Conference of Antimicrobial Agents and Chemotherapy, New Orleans, September 28–October 1, 1993
79. A. Maxwell The molecular basis of quinolone action J Antimicrob Chemother 30 1992 409 414
80. K.H. Mayer S.M. Opal A.A. Medeiros Mechanisms of antibiotic resistance Mandell G.L. Bennett J.E. Dolin R. Principles and Practice of Infectious Diseases ed 4 1995 Churchill-Livingstone New York 212
81. F. Minguez C. Ramos A. Loscos In vitro killing kinetics and postantibiotic effect of josamycin and other macrolides on several bacteria Chemother 39 1993 163 168
82. I. Morrissey C.S. Lewin J.T. Smith The influence of oxygen upon bactericidal potency Crumplin G.C. The Quinolones: Antibacterial Agents In Vitro 1990 Springer-Verlag London 23 26
83. Muñoz R. De La Campa A.G. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype Antimicrob Agents Chemother 40 1996 2252 2257
84. E. Murphy Nucleotide sequences of ermA a macrolide-lincosamide-streptogramin B determinant in Staphylococcus aureus J Bacteriol 162 1985 633 640
85. H.C. Neu Activity of macrolides against common pathogens in vitro Bryskier A.J. Butzler J.-P. Neu H.C. Macrolides 1993 Arnette Blackwell Paris 167 182
86. H.C. Neu W. Fang J.W. Gu In vitro activity of OPC-17116 Antimicrob Agents Chemother 36 1992 1310 1315
87. E.Y. Ng M. Trucksis D.C. Hooper Quinolone resistance mutations in topoisomerase IV: Relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus Antimicrob Agents Chemother 40 1996 1881 1888
88. I. Odenholt-Tornqvist E. Löwdin O. Cars Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin and azithromycin on respiratory tract pathogens Antimicrob Agents Chemother 39 1995 221 226
89. Ohshita Y, Yazaki A: In vitro studies with WQ-3034, a newly synthesized acidic fluoroquinolone [abstract F164]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 174
90. B. Olsson-Liljequist B.M. Hoffman In vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae J Antimicrob Chemother 27 Suppl A 1991 11 17
91. J. Orfila Antimycoplasmal activity of macrolides Bryskier A.J. Butzler J.P. Neu H.C. Macrolides 1993 Arnette Blackwell Paris 253 260
92. Phan LT, Or YS, Chen Y, et al: Tetracyclic ketolides: A new antibacterial macrolides. Synthesis and in vitro antibacterial activity [abstract F264]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 190
93. Phan LT, Or YS, Spina KP, et al: Tricyclic ketolides: Mono-substitution on the imine ring: Synthesis and in vitro antibacterial activity [abstract F263]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 190
94. N. Rastogi K.S. Goh In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin Antimicrob Agents Chemother 35 1991 1933 1936
95. J. Retsema A. Girard W. Schelkly Spectrum and mode of action of azithromycin (CP-62, 993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms Antimicrob Agents Chemother 31 1987 1939 1947
96. L.B. Rice R.A. Bonomo Genetic and biochemical mechanisms of bacterial resistance to antimicrobial agents Lorian Antibiotics in Laboratory Medicine ed 4 1996 Williams & Wilkins Baltimore 453 501
97. Roblin PM, Hammerschlagsuny MR: In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae [abstract F248]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 188
98. Roblin PM, Hammerschlagsuny MR: In vitro activity of a new quinolone, Y-688, against Chlamydia pneumoniae and C. trachomatis [abstract F166]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, 1997, p 174
99. K. Sato Y. Inoue T. Fujii Antibacterial activity of ofloxacin and its mode of action Infection 14 Suppl 4 1986 226 230
100. F. Scaglione S. Dugnani G. Demartini The postantibiotic effect of clarithromycin and its major human metabolite, 14-hydroxy clarithromycin J Antimicrob Chemother 32 1993 507 509
101. Schülin T, Wennersten CB, Ferraro MJ, et al: Susceptibility of Legionella spp to ketolide HMR 3647 and other newer antimicrobials [abstract F250]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, 1997, p 188
102. T. Schülin C.B. Wennersten R.C. Moellering In vitro activity of RU 64004, a new ketolide antibiotic against gram-positive bacteria Antimicrob Agents Chemother 41 1997 1196 1202
103. P.M. Shah A. Bryskier Epidemiology of resistance to macrolide antibiotics Bryskier A.J. Butzler J.P. Neu H.C. Macrolides 1993 Arnette Blackwell Paris 143 166
104. Shibata Y, Totsuka K, Shimizu K: Postantibiotic effects and effective regrowth times of new quinolones [abstract 661]. In abstracts of the ICC, Berlin, June 23–28, 1991
105. J. Sutcliffe A. Tait-Kamradt L. Wondrack Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: A common resistance pattern mediated by an efflux system Antimicrob Agents Chemother 40 1996 1817 1824
106. A. Tait-Kamradt J. Clancy M. Cronan mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae Antimicrob Agents Chemother 41 1997 2251 2255
107. Vesga O, Craig WA: Impact of macrolide resistance on the in vivo activity of a new ketolide, HMR 3647, against S. pneumoniae (SP) and S. aureus (SA) [abstract F259]. In Abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 189
108. E. Wakabayashi S. Mitsuhashi In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone Antimicrob Agents Chemother 38 1994 594 601
109. Watanabe T, Sobu K, Kanno M, et al: Antibacterial activities and postantibiotic effect of macrolide antibiotics on S. pneumoniae and M. hominis [abstract 956]. In Abstracts of the 18th International Congress of Chemotherapy, Stockholm, June 27–July 2, 1993, p 282
110. C. Webster K. Ghazan R. Slack Sub-inhibitory and post-antibiotic effects of spiramycin and erythromycin on S. aureus J Antimicrob Chemother 22 Suppl B 1988 33 39
111. B. Weisblum Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: The resistance phenotype, its biological diversity, and structural element that regulate expression—a review J Antimicrob Chemother 16 Suppl A 1985 63 90
112. Wise R, Andrews JM: The in vitro activity of the new ketolide HMR 3647 against a wide range of clinical isolates [abstract F114]. In Abstracts of the 37th International Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 165
113. J.M. Woodcock J.M. Andrews F.J. Boswell In vitro activity of BAY 12-8039, a new fluoroquinolone Antimicrob Agents Chemother 41 1997 101 106
114. Wootton M, Bowker KE, Holt HA, et al: In vitro studies with Y-688, levofloxacin (LEVO), trovafloxacin (TROVA), meropenem (MERO) and metronidazole (METRO) against over 300 anaerobe strains isolated in the United Kingdom [abstract F165]. In Abstracts of the 37th International Conference of Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997, p 174
115. W.W. Yew L.J.V. Piddock M.S.K. Li In-vitro activity of quinolones and macrolides against mycobacteria J Antimicrob Chemother 34 1994 343 351
116. Yourassowsky E. Van der Linden M.P. M.J. Lismont Rate of bactericidal activity for Bramhamella catarrhalis of a new macrolide CP-62, 933 compared to that of amoxicillin-clavulanic acid Chemotherapy 34 1988 191 194
117. R.A. Zabinski K.L. Walker A.J. Larson Effect of aerobic and anaerobic environments on staphylococcal activities of five fluoroquinolones Antimicrob Agents Chemother 39 1995 507 512